Beryl Drugs Appoints Directors Under SEBI Regulation 30 Compliance Framework

Beryl Drugs Limited announced significant board appointments through an official disclosure to BSE Limited under Regulation 30 of SEBI (LODR) Regulations 2015. The appointments were approved during the board meeting held on January 3, 2026, at the company's registered office in Indore, based on recommendations from the Nomination and Remuneration Committee.

Director Appointments and Regulatory Compliance

The board approved two key director appointments requiring shareholder approval at the upcoming general meeting. Mr. Shailendra Pathak (DIN: 11169772) was appointed as Additional Director to be regularized as Whole Time Director, while Mrs. Neha Sarda (DIN: 08456141) was designated as Independent Director (Non-Executive). The company confirmed that both appointees are not debarred from holding director positions by SEBI or any other regulatory authority.

Director Details:	Mr. Shailendra Pathak	Mrs. Neha Sarda
DIN:	11169772	08456141
Designation:	Whole Time Director	Independent Director
Age:	60 years	42 years
Date of Birth:	18.12.1965	21.12.1984
Qualifications:	Diploma in Electric Engineering	CS, M.COM
Experience:	40 years	14 years in finance and compliance
Other Directorships:	Aminova Infusions Pvt Ltd	Not disclosed

Professional Background and Expertise

Mr. Shailendra Pathak brings four decades of experience with his diploma in electrical engineering. He currently serves as a director in Aminova Infusions Private Limited and maintains no relationships with existing directors or key managerial personnel of the company. His extensive experience positions him well for the whole-time director role.

Mrs. Neha Sarda is a qualified Company Secretary and holds an M.COM degree. As a member of the Institute of Company Secretaries of India (ICSI), she brings 14 years of specialized experience in finance and compliance management. Her expertise aligns with the independent director requirements for corporate governance oversight.

Regulatory Disclosure Requirements

The appointments comply with SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, regarding director appointment disclosures. The company provided comprehensive details including professional qualifications, experience, inter-se relationships, and existing directorships as mandated under Schedule III of the Listing Regulations.

Compliance Framework:	Details
Regulation:	SEBI (LODR) Regulations 2015
Circular Reference:	SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123
Approval Required:	Shareholder approval at general meeting
Effective Date:	January 3, 2026

Corporate Governance Enhancement

The board changes reflect Beryl Drugs' commitment to strengthening corporate governance with experienced professionals in operational and oversight roles. Both appointments are subject to shareholder approval in the ensuing general meeting, ensuring proper corporate governance procedures are followed. The company also addressed related party transactions with Aminova Infusions Private Limited, requiring similar shareholder consent.

The appointments demonstrate the company's focus on bringing diverse expertise to the board, combining operational experience through the whole-time director appointment and governance oversight through the independent director position.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.63%	-0.48%	+4.09%	-3.50%	-38.94%	+138.21%

Beryl Drugs Limited has announced its financial results for the quarter ended June 30, showing a turnaround to profitability despite challenges in its manufacturing operations.

Financial Highlights

Net profit of Rs 2.11 lakhs, compared to a net loss of Rs 36.79 lakhs in Q1 of the previous year
Revenue from operations increased to Rs 483.58 lakhs, up from Rs 287.73 lakhs in the corresponding quarter
Total expenses decreased to Rs 476.61 lakhs
Basic and diluted earnings per share stood at Rs 0.04

Operational Update

The company reported that its manufacturing facility is partially under suspension and upgradation, which has impacted the turnover for the entire quarter. Despite this challenge, Beryl Drugs managed to improve its financial performance significantly compared to the same period last year.

Revenue Breakdown

Particulars	Q1 (Rs in Lakhs)	Q1 (Rs in Lakhs)
Net sales	475.43	284.51
Other operating revenues	8.15	3.22
Total Revenue	483.58	287.73

Expense Analysis

Expense Category	Q1 (Rs in Lakhs)
Cost of materials consumed	230.87
Employee benefit expense	53.39
Finance costs	10.09
Depreciation and amortisation	35.08
Other Expenses	172.52

Management Commentary

The Board of Directors approved these unaudited financial results in their meeting. The company's management noted that the partial suspension of the manufacturing facility has affected the turnover for the entire quarter. However, they have not provided specific details on when the facility is expected to return to full operation or the potential impact on future quarters.

Auditor's Review

The financial results have been subjected to a limited review by the company's statutory auditors, Subhash Chand Jain Anurag & Associates. The auditors have not expressed any material concerns in their review report.

Looking Ahead

While Beryl Drugs has shown improvement in its financial performance, investors and stakeholders will likely be watching closely for updates on the manufacturing facility's upgradation and its impact on future quarters. The company's ability to maintain profitability and potentially increase revenues once the facility is fully operational will be key factors to monitor in the coming months.

Investors are advised to consider the ongoing operational challenges and their potential impact on future performance when making investment decisions related to Beryl Drugs Limited.